CN110234640B - 作为抗癌剂的苯并咪唑衍生物 - Google Patents

作为抗癌剂的苯并咪唑衍生物 Download PDF

Info

Publication number
CN110234640B
CN110234640B CN201780070287.7A CN201780070287A CN110234640B CN 110234640 B CN110234640 B CN 110234640B CN 201780070287 A CN201780070287 A CN 201780070287A CN 110234640 B CN110234640 B CN 110234640B
Authority
CN
China
Prior art keywords
alkyl
phenyl
formula
cancer
benzimidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780070287.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110234640A (zh
Inventor
T.雷诺
I.科斯特-因弗尼兹
S.吉劳德
S.勒贝克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Claude Bernardrian First University
Lyon Public Shelter
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Leon Berard
Original Assignee
Claude Bernardrian First University
Lyon Public Shelter
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Leon Berard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Claude Bernardrian First University, Lyon Public Shelter, Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Centre Leon Berard filed Critical Claude Bernardrian First University
Publication of CN110234640A publication Critical patent/CN110234640A/zh
Application granted granted Critical
Publication of CN110234640B publication Critical patent/CN110234640B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780070287.7A 2016-09-20 2017-09-20 作为抗癌剂的苯并咪唑衍生物 Active CN110234640B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306203.7 2016-09-20
EP16306203 2016-09-20
PCT/EP2017/073801 WO2018054989A1 (en) 2016-09-20 2017-09-20 Benzoimidazole derivatives as anticancer agents

Publications (2)

Publication Number Publication Date
CN110234640A CN110234640A (zh) 2019-09-13
CN110234640B true CN110234640B (zh) 2023-04-07

Family

ID=57113229

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780070287.7A Active CN110234640B (zh) 2016-09-20 2017-09-20 作为抗癌剂的苯并咪唑衍生物

Country Status (7)

Country Link
US (2) US11384081B2 (https=)
EP (1) EP3515904B1 (https=)
JP (1) JP7278945B2 (https=)
CN (1) CN110234640B (https=)
CA (1) CA3037424A1 (https=)
ES (1) ES2973850T3 (https=)
WO (1) WO2018054989A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
CN110101685B (zh) * 2019-05-21 2021-03-30 河南大学 一种仿生纳米药物、其制备方法及应用
EP4412610A1 (en) * 2021-10-08 2024-08-14 Université Claude Bernard Lyon 1 Benzimidazole derivatives for use in the treatment or prevention of a histiocytosis or a craniopharyngioma
CN114133355B (zh) * 2021-11-29 2023-09-15 郑州大学第一附属医院 一种2-苯基-1h-苯并咪唑类衍生物及其应用
CN118908896B (zh) * 2024-09-02 2026-01-06 广东海洋大学 4-（1H-苯并[d]咪唑-2-基）-N，N-双（2-氯乙基）苯胺衍生物及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1496257A (zh) * 2001-03-12 2004-05-12 ������˹ҩƷ��˾ 调控免疫球蛋白e及抑制细胞增殖的苯并咪唑化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000516611A (ja) * 1996-08-14 2000-12-12 ワーナー―ランバート・コンパニー Ｍｃｐ―１アンタゴニストとしての２―フェニルベンズイミダゾール誘導体
CA2352554C (en) * 1998-11-27 2006-10-10 Basf Aktiengesellschaft Substituted benzimidazoles and their use as parp inhibitors
SI1194425T1 (sl) * 1999-06-23 2005-12-31 Sanofi Aventis Deutschland Substituirani benzimidazoli
US6759425B2 (en) * 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
EP1435947B1 (en) * 2001-10-19 2007-08-15 Ortho-McNeil Pharmaceutical, Inc. 2-phenyl benzimidazoles and imidazo-¬4,5|-pyridines as cds1/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
WO2005030206A1 (en) * 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
EP1960382A1 (en) * 2005-11-03 2008-08-27 ChemBridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
CN101553468A (zh) * 2006-10-18 2009-10-07 诺瓦提斯公司 有机化合物
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
BRPI0909183A2 (pt) 2008-03-20 2015-08-25 Forest Lab Holdings Ltd Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturase
US8242284B1 (en) * 2009-09-21 2012-08-14 The United States Of America As Represented By The United States Department Of Energy Anti-cancer agents based on 6-trifluoromethoxybenzimidazole derivatives and method of making
JP5819305B2 (ja) * 2009-10-13 2015-11-24 リガンド・ファーマシューティカルズ・インコーポレイテッド 造血成長因子模倣小分子化合物およびそれらの使用
WO2012102937A2 (en) 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
US20140128352A1 (en) * 2012-09-20 2014-05-08 Buck Institute For Research On Aging Compounds and methods for modulating mitochondrial metabolism and reactive oxygen species production

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1496257A (zh) * 2001-03-12 2004-05-12 ������˹ҩƷ��˾ 调控免疫球蛋白e及抑制细胞增殖的苯并咪唑化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Interaction of Hoechst 33258 mono- and bisbenzimidazole analogs with DNA;Roslov, A. A.等;《Molecular Biology (Translation of Molekulyarnaya Biologiya (Moscow))》;19971231;第31卷(第2期);228-234 *
马宇.2017800702877.《STN结构检索》.1997, *

Also Published As

Publication number Publication date
WO2018054989A4 (en) 2018-05-17
JP2019531294A (ja) 2019-10-31
EP3515904C0 (en) 2024-01-17
US11384081B2 (en) 2022-07-12
US12509465B2 (en) 2025-12-30
CN110234640A (zh) 2019-09-13
JP7278945B2 (ja) 2023-05-22
EP3515904B1 (en) 2024-01-17
US20210292328A1 (en) 2021-09-23
CA3037424A1 (en) 2018-03-29
WO2018054989A1 (en) 2018-03-29
EP3515904A1 (en) 2019-07-31
WO2018054989A9 (en) 2018-07-05
ES2973850T3 (es) 2024-06-24
US20220348587A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
CN110234640B (zh) 作为抗癌剂的苯并咪唑衍生物
CA3088927C (en) Biaryl derivative, preparation method therefor and pharmaceutical use thereof
ES2605388T3 (es) Compuesto inhibidor de Trk
CN113811300A (zh) Tead转录因子的新型小分子抑制剂
TWI865480B (zh) 抑制pge2/ep4信號傳導的化合物、其製備方法及其在醫藥上的應用
KR101342184B1 (ko) 사치환된 피리다진 헷지호그 경로 길항제
US9630932B2 (en) Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
WO2011023812A1 (en) Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
NZ574697A (en) Novel biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same
EP3083631B1 (en) Wnt pathway modulators
CN101981008A (zh) 5,6-二芳基-吡啶-2-甲酰胺衍生物、其制备方法和其作为硬骨鱼紧张肽ⅱ受体拮抗剂的治疗用途
CN101784545A (zh) 用作raf激酶抑制剂的嘧啶衍生物
CN105492008A (zh) 用于抑制fasn的新型化合物及组合物
BRPI0620066A2 (pt) derivados de ácido nicotìnico como moduladores do receptor de glutamato metabotrópico, processo para preparação dos mesmos, composição farmacêutica e uso dos referidos derivados
CN104926788B (zh) 取代哌啶类衍生物、含其的药物组合物及其在抗肿瘤中的应用
JP2017517555A (ja) 阻害剤ｐ５３−Ｍｄｍ２タンパク質−タンパク質相互作用としての、１，１’，２，５’−テトラヒドロスピロ［インドール−３，２’−ピロール］−２，５’−ジオン系を含む化合物
JP2025535036A (ja) Ｐａｒｇ阻害化合物
CN104003940A (zh) 2,4-二氟-5-(酞嗪酮-1-甲基)-苯甲酰哌嗪类化合物及其用途
EA037264B1 (ru) Гетероциклическое сульфонамидное производное и содержащее его лекарственное средство
CN105712992B (zh) 作为cMet抑制剂的化合物及其制备方法和用途
JPWO2016098793A1 (ja) 環状グアニジル基を有するチアゾール誘導体
KR20230104614A (ko) 아세트아미도-페닐벤즈아미드 유도체 및 그의 사용 방법
JPH04235983A (ja) 新規キノリン誘導体およびそれを有効成分として含有する制癌剤効果増強剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant